Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy SCIT in people aged 12 to 65 who have allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The study focuses on patients sensitized to specific house dust mites, Dermatophagoides pteronyssinus andor Dermatophagoides farinae. This is a phase 3, double-blind, placebo-controlled, randomized trial conducted at multiple centers. Participants will be randomly assigned to one of three groups two receive different doses of SCIT 10,000 TUmL or 30,000 TUmL of allergenic extract, and one receives a placebo injection without active ingredients. Treatment lasts for one year, with doses administered subcutaneously. The study compares the two active treatment groups to the placebo group to determine which dose may be more effective and safe. During the trial, participants will be closely monitored for symptoms and medication use, assessed by the Combined Symptoms and Medication Score CSMS over 12 months. Researchers will also track medication-free days, symptom-free days, quality of life related to asthma and rhinitis, adverse events, and immunological responses. Participants will log symptoms and medication use via smartphone. Safety and treatment effects will be evaluated throughout the study period.
Actively Recruiting
The trial investigates the use of the probiotic supplement Bioithas WOMAN4 as an additional treatment alongside antifungal medication for women with clinically suspected vulvovaginal candidiasis VVC. This open-label, randomized clinical trial includes a control group and focuses on evaluating symptom improvement and microbiological changes over a 4-week treatment period. The study aims to compare outcomes between women receiving only antifungal treatment and those also taking the probiotic supplement. Participants will be randomly assigned to either the treatment group, which receives the probiotic supplement in addition to prescribed antifungal therapy, or the control group, which receives antifungal treatment alone. The probiotic is provided as a bottle containing 30 capsules, taken during the 4-week intervention. The study includes two on-site visits a baseline visit where clinical data and vaginal samples are collected, and a final visit at week 4, where the same assessments are repeated, including symptom scoring and microbiological cultures. During the study visits, researchers will collect demographic and gynecological history, record symptoms such as vaginal discharge, itching, burning, irritation, and pain during intercourse, and measure vaginal pH. Vaginal samples will be cultured to detect Candida and assess Lactobacillus levels. Treatment adherence in the probiotic group will be monitored by capsule counts. The main outcome measured is the difference in symptom absence after 4 weeks between groups, along with secondary outcomes like symptom scores, microbiological culture results, and adherence. Any adverse events and additional treatments during follow-up will also be recorded.
Actively Recruiting
Researchers are conducting a national, multicenter observational study called SOGUG-PRINCIS to collect and analyze data on patients with genitourinary cancers treated with recently approved drugs under routine clinical practice in Spain. This study is both retrospective and prospective, aiming to validate real-world effectiveness of these drugs and support future funding decisions. It will serve as a registry where new subprojects will open whenever new drugs receive authorization. The study follows patients who have started treatment with specific drugs funded by the Spanish National Health System, including darolutamide combined with androgen deprivation therapy and docetaxel for hormone-sensitive prostate cancer, adjuvant nivolumab after surgery for urothelial carcinoma, and enfortumab vedotin for urothelial carcinoma. All treatments follow their approved dosing and administration guidelines and standard clinical practice. Participants progress will be monitored through routine data collection to evaluate outcomes such as progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after starting treatment. Data will be gathered from patients treated at participating centers, with follow-up continuing as per routine care. The study does not intervene in treatment decisions, which are made independently before enrollment.
Actively Recruiting
Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.
Actively Recruiting
This research aims to observe and evaluate the use of the SELUTION SLRTM sirolimus-coated balloon device in treating patients with coronary artery disease, including native vessel lesions and in-stent restenosis. It is a post-market, prospective, multicenter, international, observational study without a control group, focusing on real-world patients to assess the devices safety and effectiveness in everyday clinical practice. Participants receive treatment with the SELUTION SLRTM device as decided by their treating physician. The study monitors patients who have undergone this procedure in various clinical settings, including native coronary artery stenosis and coronary restenosis. This study does not include a comparator group and follows patients longitudinally after treatment. During participation, patients are followed up for at least 12 months to assess major adverse cardiovascular events, such as death, non-fatal heart attacks, and the need for further procedures on the treated lesions. Researchers evaluate both device-oriented and patient-oriented composite endpoints. The study collects data on treatment success shortly after the procedure and monitors safety and effectiveness outcomes over the year following treatment.